Switching Biologics in Psoriasis: First Person Dosed in New Study of Anti-IL-17 Treatment-Resistant Patients
The first psoriasis patient has been dosed in a Phase 3 clinical study of Innovent’s picankibart (recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody).